The combination of epigenetic drugs SAHA and HCI-2509 synergistically inhibits EWS-FLI1 and tumor growth in Ewing sarcoma
Oncotarget2018Vol. 9(59), pp. 31397–31410
Citations Over TimeTop 16% of 2018 papers
Daniel J. García-Domínguez, Lourdes Hontecillas‐Prieto, Pablo Rodríguez‐Núñez, Guillem Pascual‐Pasto, Mònica Vilà-Ubach, Rosa García-Mejías, María José Robles, Òscar M. Tirado, Jaume Mora, Ángel M. Carcaboso, Enrique de Álava
Abstract
The combination of SAHA and HCI-2509 is proposed as a novel treatment strategy for ES patients to inhibit the essential driver of this sarcoma and tumor growth.
Related Papers
- → Newly described translocation (18;19)(q23;q13.2) in abdominal wall soft-tissue tumor resembling Ewing sarcoma/primitive neuroectodermal tumor(2010)12 cited
- → Primary Ewing Sarcoma of the Stomach – A Newly Described Entity(2008)25 cited
- → Ewing Sarcoma and Ewing-Like Sarcoma and the Role of NKX2.2 Immunoreactivity(2021)5 cited
- → Ewing's Sarcoma Localized in the Mandible: A Case Report(2015)4 cited
- → Antimutagenic effect of 5-azacytidine in bacteria(1986)